Armata Pharmaceuticals – Page 4 – BioScience Managers

Armata Pharmaceuticals Announces Publication of Successful Adjunctive Phage Treatment in Cystic Fibrosis Patient

28th May 2019/in Armata Pharmaceuticals

Link to Full Article Armata’s bacteriophage, AP-PA01, used to treat multidrug-resistant Pseudomonas aeruginosa infection Paper appears in the peer-reviewed journal Infection Company to host bacteriophage Key Opinion Leader meeting and live webcast on Wednesday, June 26 MARINA DEL REY, Calif, May 28, 2019 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely […]

C3J Therapeutics and AmpliPhi Biosciences Announce Successful Completion of Merger and Formation of Bacteriophage Company Armata Pharmaceuticals, Inc.

9th May 2019/in Armata Pharmaceuticals

Link to Article Shares of the combined company to commence trading on the NYSE American exchange under the new symbol “ARMP” on May 10, 2019 Completed $10 million concurrent financing Ongoing collaboration with Merck to develop proprietary synthetic phage candidates MARINA DEL REY, Calif., May 9, 2019 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata”), a clinical-stage […]

AmpliPhi Biosciences Announces Stockholder Approval of Business Combination with C3J Therapeutics

8th May 2019/in Armata Pharmaceuticals

Link to Article SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that its stockholders voted to approve the proposals required to complete the business combination with C3J Therapeutics at a special meeting of AmpliPhi Biosciences stockholders held earlier today. Approximately […]

AmpliPhi Biosciences Reports Fourth Quarter and Full Year 2018 Financial Results and Business Highlights

25th March 2019/in Armata Pharmaceuticals

Link to full article Entered into a merger agreement with C3J Therapeutics that is expected to result in an NYSE American-listed company focused on development of precisely-targeted bacteriophage therapeutics $10.0 million of new capital will be invested in combined company to be re-named Armata Pharmaceuticals Preliminary Merger proxy filed with the SEC on March 25, […]

AmpliPhi Biosciences and C3J Therapeutics Agree to Merge

4th January 2019/in Armata Pharmaceuticals

Transaction to result in NYSE American-listed company focused on development of precisely-targeted bacteriophage therapeutics Merger combines AmpliPhi’s extensive phage library and Phase 1/2-ready asset with C3J’s expertise in synthetic phage and broad preclinical pipeline $10 million to be invested by existing C3J shareholders upon closing The companies plan to hold a joint conference call on […]

AmpliPhi Biosciences Successfully Optimizes Manufacturing Process and Scale Up for AB-SA01 Clinical Development

18th December 2018/in Armata Pharmaceuticals

AmpliPhi’s wholly owned GMP facility now capable of producing material for over 100,000 doses from each drug substance batch of AB-SA01, sufficient to support clinical trial requirements CATEGORY: Featured Tuesday, December 18, 2018 6:50 am EST SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEAM: APHB “The improved manufacturing productivity that we have achieved for AB-SA01 is […]

AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

8th November 2018/in Armata Pharmaceuticals

The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback Announced positive updated results from the company’s expanded access program: 21 patients with serious or life-threatening infections were treated at 7 hospitals, with 84% treatment success at the end of therapy Raised gross proceeds of $6.8 million through an […]

AmpliPhi Biosciences Announces Closing of Public Offering

16th October 2018/in Armata Pharmaceuticals

Tuesday, October 16, 2018 4:10 pm EDT PUBLIC COMPANY INFORMATION: NYSEAM: APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for patients with serious and life-threatening antibiotic-resistant bacterial infections, today announced the closing of its previously announced underwritten public offering. Gross proceeds to AmpliPhi from […]

AmpliPhi Biosciences Announces Pricing of $6.6 Million Underwritten Public Offering

12th October 2018/in Armata Pharmaceuticals

CATEGORY: Featured Friday, October 12, 2018 6:00 am EDT SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEAM: APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for patients with serious and life-threatening antibiotic-resistant bacterial infections, today announced the pricing of an underwritten public offering of 16,537,500 […]

AmpliPhi Biosciences Announces Presentation of Positive Clinical Data From its Expanded Access Program for Serious S. aureus Infections at IDWeek 2018 Conference

8th October 2018/in Armata Pharmaceuticals

13 patients with serious and life-threatening S. aureus infections were treated with AB-SA01 at the Westmead Hospital in Sydney under AmpliPhi’s expanded access program Patients suffered from severe S. aureus bacteremia and sepsis, including infective endocarditis and prosthetic valve endocarditis 83% (10 out of 12) patients in the modified intent-to-treat (mITT) population achieved treatment success […]